Hypoxia Pathway Panel New
The SwitchGear Hypoxia Panel
Hypoxia, low oxygen concentration in cells, is a characteristic of various physiological processes such as the regulation of cell differentiation, blood vessel formation, and wound healing. Hypoxia is also widely associated with diseases such as anemia, diabetes, kidney disease, cardiovascular disease, hypertension, sickle cell disease, and many cancers. Cells under hypoxic stress activate a signaling cascade of hypoxia-responsive genes to aid the cell into either adapting to the low oxygen conditions or undergoing apoptosis. This response to restore cellular homeostasis is primarily initiated and regulated by the family of hypoxia inducible transcription factors (HIF).
SwitchGear Genomics offers a comprehensive panel of cell-based reporter assays that allow you to accurately quantify transcriptional activation and repression in response to hypoxic conditions. The SwitchGear hypoxia panel helps to reveal the coordinated action of genes responsible for adaptive responses to hypoxia and the mechanism by which hypoxia-inducible factors regulate normal development and disease conditions. View a complete list of promoter constructs available in the validated Key Hypoxia Biomarker Set or the larger collection of reporters in the Extended Hypoxia Biomarker Set. SwitchGear also offers a corresponding set of 3′UTR reporters* for these key hypoxia responsive genes to understand transcript stability, translational repressions, and the effects or functions of specific miRNAs.
*UTR set not empirically validated by SwitchGear
Applications
The SwitchGear collection of hypoxia-relevant promoter reporters allows you to:
- Understand the mechanisms by which hypoxia-relevant genes are induced or repressed
- Quantify the functional consequences of transcription factor binding – while many other technologies give a qualitative view of transcription factor presence, our promoter reporter assays quantify the effects of transcription factor binding.
- Confirm data from ChIP-chip or ChIP-sequencing experiments
- Measure the effect of sequence variants and mutagenesis on promoter function
- Screen for promoter activation in the full hypoxia pathway under a multitude of conditions
Products
The SwitchGear hypoxia panel consists of following products:
| Product Name | Description | Ordering | Format |
| Key Hypoxia Biomarker Set | · 7 validated, top-responding promoters to hypoxia. Controls are ordered separately. | View list Quote form (doc) |
Standard screw cap tubes |
| Extended Hypoxia Biomarker Set | · 81 promoter reporters representing genes that respond to oxidative stress. · 7 random genomic controls · 8 transfection controls |
View list Quote form (doc) |
96-well plate |
| Hypoxia 3′UTR Set | ·3′UTR reporters corresponding to genes from hypoxia promoter collection to study translational efficiency and transcript stability. SwitchGear empirical validation not available for 3′UTR reporters | View list | 96-well plate or screw cap tubes |
The sequence-verified promoters are cloned into a custom vector containing an optimized luciferase reporter gene and are ready for transfection into living cells. The set is delivered in standard screw cap tubes or in 96-well format with each well containing a unique promoter reporter. Order the complete panels, a customized set, or an individual construct. For customized sets, please visit our online catalog SwitchDB for the desired constructs and request a quote.
Promoter Reporter Technology
Data Showcase
The SwitchGear Hypoxia Panel of promoter targets was chosen based on a combination of sequence motif analysis, expression studies, available published data regarding genes that respond to oxidative stress, as well as ChIP-chip and other binding data. The selected constructs were transfected into HT1080 cells and then exposed to two test conditions to induce the hypoxic response: 1% oxygen (under a hypoxia chamber) and 100 uM DFO (deferoxamine mesylate). The data show the highest responding promoters under our chosen test conditions. Data may differ depending on cell line and treatment conditions. View our full hypoxia validation case study.
Heat Map
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam accumsan mollis urna, eget ultricies nunc feugiat ac. Nulla facilisi. Ut vehicula metus id metus convallis cursus luctus urna viverra. Sed lorem ante, iaculis ut pretium ac, lobortis quis felis. Maecenas ornare, urna a ultricies molestie, diam nisi commodo eros, in congue augue nibh eget nunc. Nullam sed eros eros, at commodo ante.
The SwitchGear Advantage
- Quantitative: Measure promoter activity in response to hypoxia using a highly quantitative luciferase assay.
- Simple and quick: Perform your experiments today through simple transfection of our luciferase reporter constructs. No cloning or DNA preparation is needed.
- Comprehensive and verified: Choose from SwitchGear’s complete set of sequence verified and transfection ready hypoxia-relevant targets.
- Functionally insightful: Learn about the actual effects of transcription factor binding to verify computational predictions and supplement microarray or sequencing data.
- Cost-effective: Screen for promoter activation in the full hypoxia pathway under a multitude of conditions efficiently
Additional links
Hypoxia Protocol- recommended for transfection
Getting started with SwitchGear promoter constructs
Hypoxia and cancer: Application highlight
Hypoxia is a common trait in tumors, attributable to insufficient vascularization. Cell response to hypoxic stress is primarily mediated through the transcription factor hypoxia inducible factor 1 (HIF-1). Low oxygen concentration induces HIF to regulate genes involved in restoring cellular homeostasis such as erythropoietin, glycolytic enzymes, and vascular endothelial growth factor (VEGF). Understanding the regulation and mechanisms of hypoxia-induced gene expression will provide critical insights into cancer pathogenesis.
Hypoxic conditions in tumors also cause resistance to radiotherapy and chemotherapy, leading to the recent pharmaceutical interest in anti-hypoxia drug development. Although HIF-1 inhibition in hypoxic tumor cells may confer therapeutic benefits, evaluating the full HIF-1 pathway is critical for efficient screening of small molecules and minimizing off-target effects.